Imipenem: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Howard C. Berkowitz
No edit summary
Line 1: Line 1:
'''Impipenem''' is a synthetic broad-spectrum [[antibiotic]], which contains a [[beta-lactam]] ring structure but is not considered a member of the [[penicillin]] or [[cephalosporin]] class. It is a frequent choice for treatment of infections involving multidrug-resistant bacteria, or multiple types of bacteria.
'''Imipenem''' is a synthetic broad-spectrum [[antibiotic]], which contains a [[beta-lactam]] ring structure but is not considered a member of the [[penicillin]] or [[cephalosporin]] class, and is not affected by [[beta-lactamase]]s. It is a frequent choice for treatment of infections involving multidrug-resistant bacteria, or multiple types of bacteria.  Imimenem is derived from the naturally occurring antibiotic thienamycin, which is too unstable for clinical use.


It is a "semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with [[cilistatin]], a renal dipeptidase inhibitor."<ref>{{MeSH}}</ref>
"Its effectiveness is enhanced when it is administered in combination with [[cilistatin]], a renal dipeptidase inhibitor,"<ref>{{MeSH}}</ref> especially when the patient's kidney function is diminished. <ref>{{citation
| title = The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
| author = G A Verpooten, L Verbist, A P Buntinx, L A Entwistle, K H Jones,  M E De Broe
| journal = Br J Clin Pharmacol
| date = 1984 August | volume = 18 | issue = 2 | pages = 183–193
| url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1463530/}}</ref>
 
==References==
{{reflist}}

Revision as of 10:33, 27 June 2010

Imipenem is a synthetic broad-spectrum antibiotic, which contains a beta-lactam ring structure but is not considered a member of the penicillin or cephalosporin class, and is not affected by beta-lactamases. It is a frequent choice for treatment of infections involving multidrug-resistant bacteria, or multiple types of bacteria. Imimenem is derived from the naturally occurring antibiotic thienamycin, which is too unstable for clinical use.

"Its effectiveness is enhanced when it is administered in combination with cilistatin, a renal dipeptidase inhibitor,"[1] especially when the patient's kidney function is diminished. [2]

References

  1. Anonymous (2024), Imipenem (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. G A Verpooten, L Verbist, A P Buntinx, L A Entwistle, K H Jones, M E De Broe (1984 August), "The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.", Br J Clin Pharmacol 18 (2): 183–193